Improving treatment outcomes for patients with rheumatoid arthritis

Impact: Health impacts, Societal impacts, Economic impacts

Narrative

When anti-TNF therapies (which block tumour necrosis factor) were first licensed in 1999 only a few hundred patients with rheumatoid arthritis had received them, most for relatively short periods of time. Although the drugs represented a major breakthrough, ‘real-world’ effectiveness and safety were unproven. Research at the University of Manchester (UoM) has addressed this knowledge gap and has successfully refined the ways in which anti-TNF drugs are used around the world, leading directly to more effective prescribing and improved patient outcomes. The research has also provided strong evidence that women do not need to discontinue anti-TNF treatment prior to conception.

Category of impact

  • Health impacts
  • Societal impacts
  • Economic impacts
Date
2014

Related information